Gossamer Bio, Inc.

Gossamer Bio, Inc. has raised $212.1M in total funding. The most recent round was Series B.

Gossamer Bio, Inc. is headquartered in San Diego, CA.

Science Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are living with rare diseases that need better treatment options.

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational inhaled drug for PAH and PH-ILD, currently being tested in the Phase 3 PROSERA study.

Seralutinib is described as an inhaled PDGFR-alpha/beta, CSF1R, and c-KIT inhibitor delivered via a dry powder inhaler, a specific mechanism and delivery method named on the page.

Co-founded by Faheem Hasnain and Sheila Gujrathi, both former executives of Receptos, the San Diego biotech Celgene acquired for about $7.2 billion in 2015.